Why Is CLIMB BIO INC (CLYM) Stock Moving Today?

Climb Bio Inc (CLYM) stock rose 6.24% to $15.50 in morning trading on Thursday as multiple analysts raised their price targets following encouraging Phase 1 trial data for its CLYM116 compound. The stock opened at $14.60 and reached a session high of $15.50 at 10:00 AM ET, with volume at 0.3 million shares, or 0.2 times the 3-month average.

What Happened

The stock’s upward move was driven by a series of analyst upgrades. B. Riley raised its price target to $30 from $26, BTIG increased its target to $32 from $20, and Baird raised its target to $25 from $21. Piper Sandler also raised its target to $40 from $23. These actions followed the release of Phase 1 data showing that a single 320 mg dose of CLYM116 suppressed APRIL by more than 90% and IgA by 60-75% for 12 weeks in healthy volunteers. The data has generated optimism about the drug’s potential in treating IgA nephropathy, with Phase 2 data expected in the first half of 2027.

What The Data Shows

The stock has traded between $1.54 and $18.33 over the past 52 weeks. It reached an 8-session high on September 4, printing 11 fresh 52-week highs and one 52-week low. The stock has a market cap of $864.4 million, a beta of 0.08, and an unprofitable earnings profile with a trailing twelve-month EPS of -0.83. Over the last eight sessions, the stock declined 9.3% from $16.40 to $14.87 before today’s rebound.

What To Watch

Investors should monitor the company’s Phase 2 IgA nephropathy data, expected in H1 2027, as well as continued analyst coverage. The stock’s recent volatility and analyst activity suggest ongoing interest in the company’s pipeline.

Why is CLYM stock moving today?

CLIMB BIO INC (CLYM) is drawing unusual attention today. Our newswire has captured 1 story on CLYM across 1 source in the last 36 hours, with AI sentiment reading mixed (avg 52/100). The most recent driver: "Piper Sandler reiterates Climb Bio stock rating after ASN data" (Investing.com Analyst Ratings).

Is CLYM a buy right now?

Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of CLYM coverage reads 52/100 over 1 stories; treat it as a research signal and do your own diligence.

How fast does this page update?

The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.